Adlai Nortye (ANL) Total Liabilities (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Total Liabilities of $42.8 million for Q4 2025, down 6.62% year-over-year from $45.8 million in Q4 2024, and down 33.32% quarter-over-quarter from $64.1 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Total Liabilities (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Total Liabilities for 4 consecutive years, with $42.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities fell 6.62% year-over-year to $42.8 million; the TTM figure through Dec 2025 stood at $42.8 million (down 6.62% YoY), while the FY2025 annual figure was $42.8 million, down 6.62% from the prior year.
- Total Liabilities fell to $42.8 million in Q4 2025 per ANL's latest filing, from $64.1 million in the prior quarter.
- Across five years, Total Liabilities topped out at $313.9 million in Q4 2022 and bottomed at $42.8 million in Q4 2025.
- Historically, Total Liabilities has averaged $96.0 million across 4 years, with a median of $54.7 million in 2023.
- Annual changes were most pronounced in 2023 — Total Liabilities tumbled 82.43% — and 2025, when it increased 18.06%.
- Adlai Nortye's Total Liabilities stood at $313.9 million in 2022, then sank by 82.43% to $55.1 million in 2023, then slipped by 16.97% to $45.8 million in 2024, then fell by 6.62% to $42.8 million in 2025.
- Business Quant data shows ANL's Total Liabilities at $42.8 million in Q4 2025, $64.1 million in Q2 2025, and $45.8 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 33.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.53 Mn |
| Dec 31, 2025 | 42.76 Mn |
| Jun 30, 2025 | 64.12 Mn |
| Dec 31, 2024 | 45.79 Mn |
| Jun 30, 2024 | 54.31 Mn |
| Dec 31, 2023 | 55.14 Mn |
| Dec 31, 2022 | 313.89 Mn |